Barbara W. Bodem - 17 Aug 2022 Form 4 Insider Report for Turning Point Therapeutics, Inc. (TPTX)

Role
Director
Signature
/s/ Paolo Tombesi, Attorney-in-Fact
Issuer symbol
TPTX
Transactions as of
17 Aug 2022
Transactions value $
$0
Form type
4
Filing time
17 Aug 2022, 16:37:04 UTC
Previous filing
09 Jun 2022
Next filing
18 May 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TPTX Stock Option (right to buy) Disposed to Issuer -14,995 -100% 0 17 Aug 2022 Common Stock 14,995 $94.59 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Barbara W. Bodem is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 2, 2022, by and among Turning Point Therapeutics, Inc. (the "Issuer"), Bristol-Myers Squibb Company ("BMS") and Rhumba Merger Sub Inc., a wholly owned subsidiary of BMS ("Purchaser"), on August 17, 2022, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of BMS (the "Merger").
F2 At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option with an exercise price equal to or greater than $76.00, was cancelled without any consideration in respect of such cancelled option.